Overview
The honest starting point: formal drug interaction studies for NAD+ therapy have not been conducted. Approved medications go through interaction testing as part of development. Compounded preparations administered outside that pathway do not.
That absence is the reason disclosure matters more here, not less. Where a drug has been studied, the interactions are documented and predictable. Where it has not, the only protection is that whoever is treating you knows everything you take.
| Category | Why it matters |
|---|---|
| Anticoagulants and antiplatelets | Any infusion involves a needle; bleeding and bruising risk is relevant |
| Cancer treatment, current or recent | Oncology must be involved. Not a decision to make alongside |
| Immunosuppressants | Infusion and infection risk; disclose to the prescribing specialist |
| Blood pressure medication | Infusion reactions include flushing and vasodilation |
| Anything for kidney or liver disease | Affects how administered substances are handled |
| Supplements — all of them | Frequently undisclosed, and several are pharmacologically active |
| High-dose niacin with a statin | The one documented interaction in this family. See below |
The practical instruction: bring a complete list — prescriptions, over-the-counter products and supplements — to any consultation about this. "Just a supplement" is the phrase that keeps things off the record, and several of the things people classify that way are active.
Why interaction data is thin
Approved drugs go through a defined process: metabolic pathways characterized, interactions with common medications tested, findings documented in the prescribing information and updated through post-marketing surveillance.
Compounded preparations do not go through that process. There is no interaction section in a prescribing document because there is no approved prescribing document, and there is no systematic surveillance collecting outcomes.
So the available information is largely theoretical — reasoning from what NAD+ does biochemically — plus whatever individual clinicians have observed. That is a thinner basis than most people assume when they see a treatment offered in a clinical setting.
The appropriate response is not alarm. It is to make sure the decision is made by someone who knows your full picture.
The one documented interaction worth naming
Within the wider NAD+ family, there is a well-established one, and it concerns a precursor rather than NAD+ itself.
High-dose niacin (nicotinic acid) combined with a statin increases the risk of myopathy — muscle pain, weakness, and in rare cases serious muscle breakdown. This is documented, it is in the prescribing information for niacin at lipid-lowering strengths, and it is a real clinical consideration.
It is relevant here because niacin is a NAD+ precursor and appears in supplements and in "NAD+ support" products, sometimes at meaningful amounts. Anyone on a statin should mention any niacin-containing product they take.
High-dose niacin also affects blood glucose and liver enzymes, and requires monitoring at the strengths used for lipids. How niacin relates to the other precursors.
Note that nicotinamide does not carry the same lipid effects or flushing, and is a different proposition from nicotinic acid despite both being vitamin B3.
Where the theoretical concerns lie
Reasoning from mechanism rather than from data, so these are stated as considerations rather than established interactions.
Cancer treatment. NAD+ is involved in cellular metabolism and DNA repair, and several cancer therapies work by damaging DNA or disrupting metabolism. Whether supplemental NAD+ could interact with those mechanisms is not characterized. This is not something to decide alongside oncology treatment — it is something to decide with the oncology team.
PARP inhibitors deserve specific mention. They are a cancer treatment class that works on an enzyme family which consumes NAD+. Anyone on one should not add NAD+ therapy without their oncologist's involvement.
Anticoagulants and antiplatelets. Not a pharmacological interaction with NAD+ itself, but relevant to any procedure involving a needle and a cannula.
Immunosuppressants. Again, procedural rather than pharmacological — infusion carries infection risk, and that risk is different in someone immunosuppressed.
Supplements are the usual gap
This is where disclosure most often fails, and it is worth being specific about why.
People report prescriptions and omit supplements, on the reasonable-sounding basis that supplements are not medications. But several common ones are pharmacologically active in ways that matter:
St John's wort, which induces liver enzymes and affects the metabolism of a long list of medications.
High-dose vitamin E, fish oil and garlic extract, which affect bleeding.
Biotin, which does not interact pharmacologically but interferes with several laboratory immunoassays, including thyroid and hormone tests — so it can distort the panel used to work out what is going on.
DHEA and pregnenolone, which are hormone precursors rather than nutrients. Why that matters.
Other NAD+ precursors, if you are taking both an oral product and having infusions — worth mentioning so the whole picture is visible.
What to bring to the consultation
Every prescription, including anything you take occasionally.
Over-the-counter medications, including painkillers and antihistamines.
Every supplement, with the actual product rather than a category — "a B-complex" is less useful than the label.
Recent or current cancer treatment, and the name of your oncology team.
Any bleeding disorder, anticoagulation, or upcoming procedure.
Kidney or liver conditions.
And who else is treating you, so that information can flow both ways rather than sitting in two separate records.
Frequently asked questions
Does NAD+ interact with medications? Formal interaction studies have not been conducted for compounded NAD+ preparations. That absence of data is the reason to disclose everything you take rather than a reason to assume there is nothing to disclose.
Can I have NAD+ during cancer treatment? Not without your oncology team's involvement. NAD+ is involved in DNA repair and cellular metabolism, which are processes several cancer treatments act on.
What about niacin and my statin? High-dose niacin with a statin increases myopathy risk, and this is documented. Mention any niacin-containing product if you are on a statin.
Do I need to mention supplements? Yes — several are pharmacologically active, and biotin in particular interferes with laboratory tests including thyroid and hormone assays.
What if I am on blood thinners? Worth disclosing, mainly because any infusion involves a needle and cannula. It is a procedural consideration rather than a known pharmacological interaction.
Where this fits in your plan
The most valuable thing you can do here is arrive with a complete list, including the things that do not feel like medications.
That is what allows a decision to be made on your actual picture — and it matters more, not less, in an area where the formal interaction data is thin. What we check, and what NAD+ therapy involves here.
We measure first. Then we act.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
